Company intelligence / Profile preview
Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Ownership
- Private
- Employees
- ~2545
- Development stage
- Other
Overview
Heilongjiang ZBD Pharmaceutical has multiple approved products in China—mainly traditional Chinese medicine formulations for cardiovascular and respiratory diseases. The company also has novel small molecule programs in early clinical development targeting oncology and infectious diseases. Recent financial reports show strong revenue growth driven by both legacy TCM products and new drug launches. Some recent regulatory setbacks have occurred but the overall pipeline remains robust
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- Small molecule drugsherbal medicinesbiological agents
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Heilongjiang ZBD Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heilongjiang ZBD Pharmaceutical Co., Ltd..